The Pharma Data

JANUARY 31, 2021

(NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Sequoia Capital China , a leading investment firm, today announced a collaboration to catalyze the startup ecosystem in China with the launch of the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.

Genome 52

Genome Genomics Life Science DNA 52

The Pharma Data

JANUARY 24, 2021

Bond joins Notch from Kite, where he most recently served as Vice President of Cellular Engineering. Dr. Bond has extensive experience in the discovery and development of adoptive cell therapies, monoclonal antibodies, and cellular engineering and genome editing. ” Chris Bond , Ph.D.,

Engineer 52

Engineer Gene Editing Genomics Genome 52

XTalks

JANUARY 21, 2025

From non-invasive cancer diagnostics to life-saving cardiovascular implants, the latest medical devices cleared or approved by the FDA in 2024 reflect the remarkable strides in science and engineering. The Onclarity HPV reagent pack extraction combo. Photo courtesy of BD. The diagnostic tests for more than 500 genes to profile tumors.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

Advarra

NOVEMBER 29, 2022

Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline. But review issues are not the only problems.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

pharmaphorum

FEBRUARY 3, 2021

These treatments are examples of patient-specific, engineered chimeric antigen receptor (CAR)-T cell therapies that harness the immune system to target and eliminate cancer cells. Thus, the availability of universal, “off-the-shelf” engineered T cells presents an attractive alternative.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

XTalks

JANUARY 6, 2025

Additionally, CRISPR genome-wide screening holds great potential for identifying key disease-associated genes and uncovering novel therapeutic targets. NGS technology has revolutionized genetic analysis, enabling laboratories to rapidly sequence whole genomes, deeply sequence target regions and identify novel pathogens.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111